

DAFTAR PUSTAKA

- Adeloka K, Rosen ST, Shanmugam M. Glucose Transporters In Cancer Metabolism. *Curr Opin Oncol*. 2012 Nov;24(6):650-654
- Ambros V (Dec 2001). "microRNAs: tiny regulators with great potential". *Cell*. 107 (7): 823–6.
- Aune D, Lau R, Chan DS, Vieira R, Greenwood DC, Kampman E, et al. Dairy products and colorectal cancer risk: a systematic review and meta-analysis of cohort studies. *Ann Oncol*. 2012 Jan;23(1):37-45
- Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, Saltzman WM, Slack FJ. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. *Proc Natl Acad Sci U S A*. 2012 Jun 26;109(26):E1695-1704
- Bird, A. DNA methylation patterns and epigenetic memory. *Genes Dev*. 2002 Jan 1;16(1):6-21.
- Bray F, Ferlay J, Soerjomataram I, Rebecca L, Siegel, Torre, Jemal A. Global cancer Statistics 2018: GLOBOCAN Estimates Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*. 2018 Nov;68(6):394-424
- Brophy S, Sheehan KM, McNamara DA, Deasy J, Bouchier-Hayes DJ, Kay EW. GLUT-1 expression and response to chemoradiotherapy in rectal cancer. *Int J Cancer*. 2009 Dec 15;125(12):2778-2782
- Bujko K1, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Pudelko M, Kryj M, Oledzki J, Szmaja J, Słuszniak J, Serkies K, Kładny J, Pamucka M, Kukołowicz P. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. *Radiother Oncol*. 2004 Jul;72(1):15-24.
- Chang S, Wang R-H, Akagi K, et al. Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. *Nat Med*. 2011;17:1275–82.
- Chen S, Li P, Li J, Wang Y, Du Y, Chen X, Zang W, Wang H, Chu H, Zhao G, Zhang G. miR-144 inhibits proliferation and induces apoptosis and autophagy in lung cancer cells by targeting TIGAR. *Cell Physiol Biochem*. 2015;35(3):997-1007

- Chiba I, Ogawa K, Morioka T, Shimoji H, Sunagawa N, Iraha S, Nishimaki T, Yoshimi N, Murayama S. Clinical significance of GLUT-1 expression in patients with esophageal cancer treated with concurrent chemoradiotherapy. *Oncol Lett.* 2011 Jan;2(1):21-28
- Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, Muller RU, Straka E, Su L, Burki EA, Crowell RE, Patel R, Kulkarni T, Homer R, Zelterman D, Kidd KK, Zhu Y, Christiani DC, Belinsky SA, Slack FJ, Weidhaas JB. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. *Cancer Res.* 2008 Oct 15;68(20):8535-8540
- Cipolla GA, Park JK, de Oliveira LA, Lobo-Alves SC, de Almeida RC, Farias TD, Lemos Dde S, Malheiros D, Lavker RM, Petzl-Erler ML. A 3'UTR polymorphism marks differential KLRG1 mRNA levels through disruption of a miR-584-5p binding site and associates with pemphigus foliaceus susceptibility. *Biochim Biophys Acta.* 2016 Oct;1859(10):1306-1313
- Conway AM, Mitchell C, Kilgour E, Brady G, Dive C, Cook N. Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the 'U' out of 'CUP'. *British Journal of Cancer* volume 120, pages141–153 (2019)
- Courtney R, Ngo DC, Malik N, Ververis K, Tortorella SM, Karagiannis TC. Cancer Metabolism and the Warburg Effect: the role of HIF-1 and PI3K. *Mol Biol Rep.* 2015 Apr;42(4):841-851
- Dalman MR, Deeter A, Nimishakavi G, Duan ZH. Fold change and p-value cutoffs significantly alter microarray interpretations. *BMC Bioinformatics.* 2012 Mar 13;13 Suppl 2:S11
- Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, Corless CL, Debiec-Rychter M, DeMatteo RP, Ettinger DS, Fisher GA, Fletcher CD, Gronchi A, Hohenberger P, Hughes M, Joensuu H, Judson I, Le Cesne A, Maki RG, Morse M, Pappo AS, Pisters PW, Raut CP, Reichardt P, Tyler DS, Van den Abbeele AD, von Mehren M, Wayne JD, Zalcborg J; NCCN Task Force. NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice Guidelines. *J Natl Compr Canc Netw.* 2007 Jul;5 Suppl 2:S1-29; quiz S30
- Du B, Wu D, Yang X, Wang T, Shi X, Lv Y, Zhou Z, Liu Q, Zhang W. The expression and significance of microRNA in different stages of colorectal cancer. *Medicine (Baltimore).* 2018 Feb;97(5):e9635.
- Ekat Kritikou. 2008. Colorectal cancer. *Nature Reviews Molecular Cell Biology*

Nature Publishing Group. nature reviews | cancer.

- Fan JY, Yang Y, Xie JY, Lu YL, Shi K, Huang YQ. MicroRNA-144 mediates metabolic shift in ovarian cancer cells by directly targeting GLUT1. *Tumour Biol.* 2016 May;37(5):6855-6860
- Ferlay, J, Soerjomataram, I, Dikshit, R, Eser, S, Mathers, C, Rebelo, M, Parkin, DM, Forman, D dan Bray, F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer.* 2015 Mar 1;136(5):E359-386
- Fleming M, Ravula S, Tatishchev, SF, Wang HL. Colorectal carcinoma: Pathologic aspects. *J Gastrointest Oncol.* 2012 Sep;3(3):153-73
- Garcia AI, Buisson M, Bertrand P, et al. Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. *EMBO Mol Med.* 2011;3:279-90.
- Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM. MicroRNA expression and function in cancer. *Trends Mol Med.* 2006 Dec;12(12):580-587
- Graham LD, Pedersen SK, Brown GS, Ho T, Kassir Z, Moynihan AT, Vizgoft EK, Dunne R, Pimlott L, Young GP, Lapointe LC, Molloy PL. Colorectal Neoplasia Differentially Expressed (CRNDE), a Novel Gene with Elevated Expression in Colorectal Adenomas and Adenocarcinomas. *Genes Cancer.* 2011 Aug;2(8):829-840
- Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. *Clin Colon Rectal Surg.* 2009 Nov;22(4):191-197
- Hanahan D. Weinberg RA. 2011. Review Hallmarks of Cancer: The Next Generation. *Cell.* 2011 Mar 4;144(5):646-674.
- Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR, Hollmig K, Zangarri M, Pineda-Roman M, van Rhee F, Cavallo F, Burington B, Crowley J, Tricot G, Barlogie B, Shaughnessy JD Jr. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. *Blood.* 2006 Sep 1;108(5):1724-1732
- Hessvik NP, Sandvig K, Llorente A. 2013. Exosomal miRNAs as biomarkers for prostate cancer. *Front Genet.* 2013 Mar 21;4:36.
- Hue L, Beauloye C, Marsin AS, Bertrand L, Horman S, Rider MH. Insulin and

ischemia stimulate glycolysis by acting on the same targets through different and opposing signaling pathways. *J Mol Cell Cardiol.* 2002 Sep;34(9):1091-1097

Iwaya T, Yokobori T, Nishida N, Kogo R, Sudo T, Tanaka F, Shibata K, Sawada G, Takahashi Y, Ishibashi M, Wakabayashi G, Mori M, Mimori K. Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway. *Carcinogenesis.* 2012 Dec;33(12):2391-2397

Imperiale TF, Ransohoff DF. Risk for colorectal cancer in persons with a family history of adenomatous polyps: a systematic review. *Ann Intern Med.* 2012 May 15;156(10):703-709

Jong D. Buku Ajar Ilmu Bedah. In: Riwanto Ignatius, Hamami AH, Pieter John, Tjambolang Tadjuddin Ahmadsyah Ibrahim. 2013. *Usus Halus, Appendiks, Kolon, dan Anorektum.* Jakarta: EGC. 731-798.

Karolina DS, Armugam A, Tavintharan S, Wong MT, Lim SC, Sum CF, Jeyaseelan K (2011). "MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus". *PLOS ONE.* 6 (8): e22839

Kemenkes RI. 2015. Buletin Jendela Data dan Informasi Kesehatan. ISSN 2088

Krzeslak A, Wojcik-Krowiranda K, Forma E, Jozwiak P, Romanowicz H, Bienkiewicz A, Brys M. Expression of GLUT1 and GLUT3 glucose transporters in endometrial and breast cancers. *Pathol Oncol Res.* 2012 Jul;18(3):721-728.

Kumar V, Abbas AK, Fausto N. 2010. *Dasar Patologis Penyakit; Robbins & Cotran.* Edisi ketujuh. Diterjemahkan oleh Hartono Andry. Jakarta: EGC.

Kurniawati A, Tenggara R. Pengaruh Asam Asetil Salisilat terhadap Penurunan Prevalensi Kanker Kolorektal. *Cermin Dunia Kedokteran* 38 (5) 2011 : 350-352.

Larsson SC, Bergkvist L, Wolk A. Magnesium intake in relation to risk of colorectal cancer in women. *JAMA.* 2005 Jan 5;293(1):86-9

Levati L, Pagani E, Romani S, Castiglia D, Piccinni E, Covaciu C, Caporaso P, Bondanza S, Antonetti FR, Bonmassar E, Martelli F, Alvino E, D'Atri S. MicroRNA-155 targets the SKI gene in human melanoma cell lines. *Pigment Cell Melanoma Res.* 2011 Jun;24(3):538-550

- Li CL, Nie H, Wang M, Su LP, Li JF, Yu YY, Yan M, Qu QL, Zhu ZG, Liu BY. microRNA-155 is downregulated in gastric cancer cells and involved in cell metastasis. *Oncol Rep.* 2012 Jun;27(6):1960-1966
- Li L, Zhang J, Diao W, et al. MicroRNA-155 and microRNA-21 promote the expansion of functional myeloid-derived suppressor cells. *J Immunol.* 2014;192:1034-43.
- Liu J, Xue H, Zhang J, Suo T, Xiang Y, Zhang W, Ma J, Cai D, Gu X. MicroRNA-144 inhibits the metastasis of gastric cancer by targeting MET expression. *J Exp Clin Cancer Res.* 2015 Apr 17;34:35
- Liu M, Gao J, Huang Q, Jin Y, Wei Z. 2016. Downregulating microRNA-144 mediates a metabolic shift in lung cancer cells by regulating GLUT1 expression. *Oncol Lett.* 2016 Jun;11(6):3772-3776
- Lu K, Yang J, Li DC, He SB, Zhu DM, Zhang LF, Zhang X, Chen XC, Zhang B, Zhou J. Expression and clinical significance of glucose transporter in pancreatic cancer. *Oncol Lett.* 2016 Jul;12(1):243-249
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods.* 2001 Dec;25(4):402-408
- Maier T, Guëll M, Serrano L. Correlation of mRNA and protein in complex biological samples. *Febs Lett.* 2009;583:3966-73.
- Misiewicz-Krzeminska I, Krzeminski P, Corchete LA, Quwaider D, Rojas EA, Herrero AB, Gutiérrez NC. Factors Regulating microRNA Expression and Function in Multiple Myeloma. *Noncoding RNA.* 2019 Jan 16;5(1). pii: E9
- Monson JR, Weiser MR, Buie WD, Chang GJ, Rafferty JF, Buie WD, Rafferty J; Standards Practice Task Force of the American Society of Colon and Rectal Surgeons. Practice parameters for the management of rectal cancer (revised). *Dis Colon Rectum.* 2013 May;56(5):535-550
- Marley AR, Nan H. Epidemiology of colorectal cancer. *Int J Mol Epidemiol Genet.* 2016 Sep 30;7(3):105-114
- Malhotra R, Brosius FC 3rd. Glucose uptake and glycolysis reduce hypoxia-induced apoptosis in cultured neonatal rat cardiac myocytes. *J Biol Chem.* 1999 Apr 30;274(18):12567-12575
- Matsushita R, Seki N, Chiyomaru T, Inoguchi S, Ishihara T, Goto Y, Nishikawa R, Mataka H, Tatarano S, Itesako T, Nakagawa M, Enokida H. Tumour-suppressive microRNA-144-5p directly targets CCNE1/2 as

- potential prognostic markers in bladder cancer. *Br J Cancer*. 2015 Jul 14;113(2):282-289
- McCourt M, Armitage J, Monson JR. Rectal cancer. *The Surgeon*. 2009;7(3):162-9.
- Namløs HM, Meza-Zepeda LA, Barøy T, Østensen IH, Kresse SH, Kuijjer ML, Serra M, Bürger H, Cleton-Jansen AM, Myklebost O. Modulation of the osteosarcoma expression phenotype by microRNAs. *PLoS One*. 2012;7(10):e48086
- O'Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. *Front Endocrinol (Lausanne)*. 2018 Aug 3;9:402
- Ohba S, Fujii H, Ito S, Fujimaki M, Matsumoto F, Furukawa M, Yokoyama J, Kusunoki T, Ikeda K, Hino O. Overexpression of GLUT-1 in the invasion front is associated with depth of oral squamous cell carcinoma and prognosis. *J Oral Pathol Med*. 2010 Jan;39(1):74-78
- Palma CA, Al Sheikha D, Lim TK, Bryant A, Vu TT, Jayaswal V, Ma DD. MicroRNA-155 as an inducer of apoptosis and cell differentiation in Acute Myeloid Leukaemia. *Mol Cancer*. 2014 Apr 5;13:79
- Pan Y, Zhang J, Fu H, Shen L. miR-144 functions as a tumor suppressor in breast cancer through inhibiting ZEB1/2-mediated epithelial mesenchymal transition process. *Oncotargets Ther*. 2016 Oct 11;9:6247-6255
- Parish B, Ign. Riwanto, Maleachu, Kunsemedi S. Report Incidence of Colorectal Cancer in Dr. Kariadi General Hospital Semarang 2009-2010. *1st Makassar Colorectal Cancer Conference*: 2011 Jun 2-4.
- Petrovic N, Ergün S, Isenovic ER. Levels of MicroRNA Heterogeneity in Cancer Biology. *Mol Diagn Ther*. 2017 Oct;21(5):511-523.
- Pinheiro M, Ahlquist T, Danielsen SA, Lind GE, Veiga I, Pinto C, Costa V, Afonso L, Sousa O, Fragoso M, Santos L, Henrique R, Lopes P, Lopes C, Lothe RA, Teixeira MR. Colorectal carcinomas with microsatellite instability display a different pattern of target gene mutations according to large bowel site of origin. *BMC Cancer*. 2010 Oct 27;10:587
- Plas DR, Talapatra S, Edinger AL, Rathmell JC, Thompson CB. Akt and Bcl-xL promote growth factor-independent survival through distinct effects on mitochondrial physiology. *J Biol Chem*. 2001 Apr 13;276(15):12041-12048
- Qin W, Ren Q, Liu T, Huang Y, Wang J. MicroRNA-155 is a novel suppressor of

ovarian cancer-initiating cells that targets CLDN1. *FEBS Lett.* 2013 May 2;587(9):1434-1439.

Rasmussen KD, Simmini S, Abreu-Goodger C, Bartonicek N, Di Giacomo M, Bilbao-Cortes D, Horos R, Von Lindern M, Enright AJ, O'Carroll D. The miR-144/451 locus is required for erythroid homeostasis. *J Exp Med.* 2010 Jul 5;207(7):1351-8.

Registries A.I.o.H.a.W.A.A.o.C. 2012. *Cancer in Australia: an overview.* AIHW, Canberra

Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. *Lancet.* 2008 Feb 16;371(9612):569-578

Rupaimoole R, Calin GA, Lopez-Berestein G2, Sood AK. miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. *Cancer Discov.* 2016 Mar;6(3):235-246

Schmittgen TD. Regulation of microRNA processing in development, differentiation and cancer. *J Cell Mol Med.* 2008 Oct;12(5B):1811-1819.

Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, Quirke P, Couture J, de Metz C, Myint AS, Bessell E, Griffiths G, Thompson LC, Parmar M. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. *Lancet.* 2009 Mar 7;373(9666):811-820

Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, Kopetz SE, Lieu C, Lindor NM, Minsky BD, Monzon FA, Sargent DJ, Singh VM, Willis J, Clark J, Colasacco C, Rumble RB, Temple-Smolkin R, Ventura CB, Nowak JA. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. *J Clin Oncol.* 2017 May 1;35(13):1453-1486

Shen J, Stass SA, Jiang F. MicroRNAs as potential biomarkers in human solid tumors. *Cancer Lett.* 2013 Feb 28;329(2):125-136.

Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. *CA Cancer J Clin.* 2014 Mar-Apr;64(2):104-17

Steel GG, Peacock JH. Why are some human tumours more radiosensitive than others? *Radiother Oncol.* 1989;15(1):63-72.

- Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. *Int J Radiat Oncol Biol Phys.* 1979;5(1):85–91
- Svoronos AA, Engelman DM, Slack FJ. OncomiR or Tumor Suppressor? The Duplicity of MicroRNAs in Cancer. *Cancer Res.* 2016 Jul 1;76(13):3666-3670
- Vander Heiden MG, Cantley LC, Thompson CB. 2009. Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science.* 2009 May 22;324(5930):1029-1033.
- Vaupel P, Schlenger K, Knoop C, Hockel M. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O₂ tension measurements. *Cancer Res.* 1991;51(12):3316–3322.
- Wang W, Peng B, Wang D, Ma X, Jiang D, Zhao J, Yu L (Oct 2011). "Human tumor microRNA signatures derived from large-scale oligonucleotide microarray datasets". *Int J Cancer.* 2011 Oct 1;129(7):1624-34..
- Warburg O, Wind F, Negelein E. 1927. THE METABOLISM OF TUMORS IN THE BODY. *J Gen Physiol.* 1927 Mar 7;8(6):519-530.
- Wei EK, Giovannucci E, Wu K, Rosner B, Fuchs CS, Willett WC, Colditz GA. Comparison of risk factors for colon and rectal cancer. *Int J Cancer.* 2004 Jan 20;108(3):433-42
- Weichselbaum RR, Little JB. Radioresistance in some human tumor cells conferred in vitro by repair of potentially lethal X-ray damage. *Radiology.* 1982;145(2):511–513.
- WHO IAFRIC. *Globocan 2012 Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012.* 2012; v. 2013. [cited 2013 Nov 20]. Available from : http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
- Wincewicz A, Sulkowska M, Koda M, Kanczuga-Koda L, Witkowska E, Sulkowski S. Significant coexpression of GLUT-1, Bcl-xL, and Bax in colorectal cancer. *Ann N Y Acad Sci.* 2007 Jan;1095:53-61.
- World Health Organization, 2014. *Cancer Country Profiles: Indonesia.* Cancer Ctry. Profiles. Hal. 22-23.
- Wolff HA, Daldrup B, Jung K, Overbeck T, Hennies S, Matthias C, Hess CF, Roedel RM, Christiansen H. High-grade acute organ toxicity as positive

prognostic factor in adjuvant radiation and chemotherapy for locally advanced head and neck cancer. *Radiology*. 2011;258(3):864–871.

Wu K, Willett WC, Fuchs CS, Colditz GA, Giovannucci EL. Calcium intake and risk of colon cancer in women and men. *J Natl Cancer Inst*. 2002 Mar 20;94(6):437-46

Wu L, Qu X. Cancer biomarker detection: recent achievements and challenges. *Chem Soc Rev*. 2015 May 21;44(10):2963-2997

Xiao J, Tao T, Yin Y, Zhao L, Yang L, Hu L. miR-144 may regulate the proliferation, migration and invasion of trophoblastic cells through targeting PTEN in preeclampsia. *Biomed Pharmacother*. 2017 Oct;94:341-353

Yu L, Chen X, Sun X, Wang L, Chen S. 2017. The glycolytic Switch in Tumors: How many Players Are Involved?. *J Cancer*. 2017 Sep 20;8(17):3430-3440.

Zaider M, Hanin L. Tumor control probability in radiation treatment. *Med Phys*. 2011;38(2):574–583.

Zhang J, Li S, Li L, Li M, Guo C, Yao J, Mi S. Exosome and exosomal microRNA: Trafficking, sorting, and function. *Genomics Proteomics Bioinformatics*. 2015 Feb;13(1):17-24.

Zhang X, Wang X, Zhu H, Zhu C, Wang Y, Pu WT, Jegga AG, Fan GC. Synergistic effects of the GATA-4-mediated miR-144/451 cluster in protection against simulated ischemia/reperfusion-induced cardiomyocyte death. *J Mol Cell Cardiol*.. 2010. 49(5): 841–50.